….while hospitalizations are down. Full Article
Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) covers five more HPV types than predecessor Gardasil, both manufactured by Merck Sharp & Dohme Corp., subsidiary of Merck & Co. Click here for the full story.
Earn an educational grant from CPP to help offset the cost of investing in proper vaccine storage equipment. Educate yourself on the new CDC guidelines published in 2012 to make sure you aren’t putting your vaccine stock at risk. CPP provides educational resources around proper vaccine storage that include a list of recommended units from other CPP members.
Through the implementation of enhanced temperature monitoring procedures, many of our member practices have discovered failures in their refrigerators and freezers that have previously gone undetected. This discovery has led them to purchase new equipment that complies with the new guidelines, develop new procedures for greater oversight and create contingency plans in case of equipment or process failure. As you can imagine, this can be a very expensive venture for your practice but it could be even more expensive if you were to lose thousands of dollars’ worth of vaccines. CPP will continue to support our member offices in protecting their vaccine investments.
Infants were hit particularly hard as officials call for greater efforts to vaccinate pregnant women. Click here for the full article.
Many CPP members have utilized the “Vaccine Safety and your Child” booklet authored by Dr. Paul Offit and Charlotte Moser when discussing vaccines with patients and their families. A read-only version is available online or the booklets can be purchased for $1 each through the Children’s Hospital of Philadelphia (CHOP) Vaccine Education Center.
Please tell us what resources work well for you and your practice so that we can share with other CPP members!
The Children’s Hospital of Philadelphia (CHOP) and the AAP Pennsylvania Chapter sponsored a webinar discussing current issues in vaccines. Dr. Paul Offit discussed the following:
- Conflicting data and AAP recommendation regarding the use of Flumist in patients aged 2-8 years
- Expectations for the next generation 9-valent HPV that is awaiting FDA approval
- Anticipated utilization of the new meningococcal B vaccines
Click here to access the webinar.